(Q39559549)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21487605%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

title

A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21487605%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21487605%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

Usha Varadarajan

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21487605%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Sung Choe

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21487605%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Yan Liu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21487605%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

John McGraw

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21487605%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Matthew Woods

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21487605%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Stuart Murray

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21487605%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Amy Eckert

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21487605%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Wei Liu

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21487605%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Terence E Ryan

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21487605%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

publication date

12 April 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21487605%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21487605%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21487605%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21487605%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

1974-1989

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21487605%20AND%20SRC:MED&resulttype=core&format=json

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

28 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Antitumor activity of HER-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Molecular classification and molecular forecasting of breast cancer: ready for clinical application?

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

What is triple-negative breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

How basal are triple-negative breast cancers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Gene expression profiling of breast cell lines identifies potential new basal markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Killing the messenger: short RNAs that silence gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Mechanisms of gene silencing by double-stranded RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Ribo-gnome: the big world of small RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

RNAi screening for the discovery of novel modulators of human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Establishment of a chemical synthetic lethality screen in cultured human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

shRNA libraries and their use in cancer genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Use of RNA interference libraries to investigate oncogenic signalling in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Dissecting cancer pathways and vulnerabilities with RNAi

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Cancer proliferation gene discovery through functional genomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Profiling essential genes in human mammary cells by multiplex RNAi screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

A loss-of-function RNA interference screen for molecular targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Synthetic lethal screen identification of chemosensitizer loci in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Cancer: Deconstructing oncogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Chemical combination effects predict connectivity in biological systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Integrated functional, gene expression and genomic analysis for the identification of cancer targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Normalization of cDNA microarray data

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

A chemical screen identifies anisomycin as an anoikis sensitizer that functions by decreasing FLIP protein synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Combination chemical genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Principles of cancer therapy: oncogene and non-oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Non-oncogene addiction and the stress phenotype of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Utilizing RNA interference to enhance cancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Role of the progesterone receptor for paclitaxel resistance in primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

Synergistic drug combinations tend to improve therapeutically relevant selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1039%2FC0MB00294A

21 January 2018

Identifiers

DOI

10.1039/C0MB00294A

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21487605%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference